Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 12;10(6):323.
doi: 10.3390/v10060323.

Phage Therapy Faces Evolutionary Challenges

Affiliations

Phage Therapy Faces Evolutionary Challenges

Clara Torres-Barceló. Viruses. .

Abstract

Antibiotic resistance evolution in bacteria indicates that one of the challenges faced by phage therapy is that, sooner or later, bacteria will evolve resistance to phages. Evidently, this is the case of every known antimicrobial therapy, but here this is also part of a ubiquitous natural process of co-evolution between phages and bacteria. Fundamental evolutionary studies hold some clues that are crucial to limit the problematic process of bacterial resistance during phage applications. First, I discuss here the importance of defining evolutionary and ecological factors influencing bacterial resistance and phage counter-defense mechanisms. Then, I comment on the interest of determining the co-evolutionary dynamics between phages and bacteria that may allow for selecting the conditions that will increase the probability of therapeutic success. I go on to suggest the varied strategies that may ensure the long-term success of phage therapy, including analysis of internal phage parameters and personalized treatments. In practical terms, these types of approaches will define evolutionary criteria regarding how to develop, and when to apply, therapeutic phage cocktails. Integrating this perspective in antimicrobial treatments, such as phage therapy, is among the necessary steps to expand its use in the near future, and to ensure its durability and success.

Keywords: bacterial resistance; evolution; phage therapy; virulence.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest. The founding sponsors had no role in the writing of the manuscript.

Figures

Figure 1
Figure 1
Different factors to consider in phage therapy applications in order to ensure the durability of the strategy against pathogenic bacteria. Color code associates the factors to therapeutic phages (blue), the targeted bacteria (red), or both microorganisms and the interaction between them (violet).

Similar articles

Cited by

References

    1. Kingwell K. Bacteriophage therapies re-enter clinical trials. Nat. Rev. Drug Discov. 2015;14:515–516. doi: 10.1038/nrd4695. - DOI - PubMed
    1. Buttimer C., McAuliffe O., Ross R.P., Hill C., O’Mahony J., Coffey A. Bacteriophages and Bacterial Plant Diseases. Front. Microbiol. 2017;8 doi: 10.3389/fmicb.2017.00034. - DOI - PMC - PubMed
    1. Moye Z., Woolston J., Sulakvelidze A. Bacteriophage Applications for Food Production and Processing. Viruses. 2018;10:205. doi: 10.3390/v10040205. - DOI - PMC - PubMed
    1. Casey E., van Sinderen D., Mahony J. In Vitro Characteristics of Phages to Guide “Real Life” Phage Therapy Suitability. Viruses. 2018;10:163. doi: 10.3390/v10040163. - DOI - PMC - PubMed
    1. Rohde C., Resch G., Pirnay J.-P., Blasdel B.G., Debarbieux L., Gelman D., Górski A., Hazan R., Huys I., Kakabadze E., et al. Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains. Viruses. 2018;10:178. doi: 10.3390/v10040178. - DOI - PMC - PubMed

Publication types

Substances

LinkOut - more resources